Antibody · 다발성 골수종

AntibodySHOTFDACuratedFDABiologicJanssenApproved

daratumumab (Darzalex)

Multiple myeloma · CD38

#CD38#Antibody#Approved#FDA승인#바이오모아추천+5

효능 ORR 97%임상시험 342상태 APPROVED

AntibodyHotJanssenApproved

Infliximab (Infliximab)

Cytokine Release Syndrome; Recurrent Multiple Myeloma · Crohn Disease

#CrohnDisease#Antibody#Approved#인기#항체+5

효능 ORR 54.5%임상시험 283상태 ACTIVE

AntibodyAHotRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#인기#항체+5

효능 ORR 95%임상시험 115상태 RECRUITING

AntibodyCJanssenPhase 2

Tec (Teclistamab, Teclistamab (Tec))

AL Amyloidosis · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#인기#항체+4

임상시험 88상태 RECRUITING

AntibodyGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#인기#항체+5

효능 ORR 77.3%임상시험 64상태 ACTIVE

AntibodyBristol Myers Squibbvedotin in patients with re…Phase 2

nivolumab (Opdivo, Nivolumab and Ipilimumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#인기#항체+5

효능 ORR 77.8%임상시험 62상태 RECRUITING

AntibodyJanssenApproved

Teclistamab (Teclistamab)

Myeloma Multiple; Plasma Cell Leukemia · Myeloma Multiple

#MyelomaMultiple#Antibody#Approved#인기#항체+5

임상시험 60상태 RECRUITING

AntibodyPfizerPhase 3

Elotuzumab (Elotuzumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+4

효능 ORR 100%임상시험 57상태 RECRUITING

AntibodyIndapta Therapeutics, INC.Phase 3

Isatuximab (Isatuximab)

NHL; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+5

효능 ORR 67%임상시험 56상태 RECRUITING

AntibodyPfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5

효능 ORR 61%임상시험 54상태 RECRUITING

AntibodyRegeneronPhase 2

Cemiplimab REGN2810 (Cemiplimab REGN2810)

Plasma Cell Myeloma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5

효능 ORR 55.6%임상시험 51상태 ACTIVE

AntibodyPfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5

효능 ORR 61%임상시험 51상태 ACTIVE

AntibodyJack Khouri, MDPhase 2

Siltuximab (Siltuximab)

Multiple Myeloma; Cytokine Release Syndrome · Myelofibrosis

#Myelofibrosis#Antibody#Phase2#항체#면역항체+5

효능 ORR 46.7%임상시험 43상태 RECRUITING

AntibodyJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#항체#면역항체+5

임상시험 40상태 DISCONTINUED

AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab plus Ipilimumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5

효능 ORR 77.8%임상시험 32상태 RECRUITING

AntibodyRochederuxtecan, are effective i…Phase 2

trastuzumab (Herceptin, Trastuzumab plus Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5

효능 ORR 79.5%임상시험 32상태 RECRUITING

AntibodystaleSanofiPhase 3

Isatuximab SAR650984 (Isatuximab SAR650984)

Immune System Disorder · Plasma Cell Myeloma

#PlasmaCellMyeloma#Antibody#Phase3#항체#면역항체+3

효능 ORR 55.6%임상시험 31상태 ACTIVE

AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab and Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5

효능 ORR 69.3%임상시험 31상태 RECRUITING

AntibodystaleGilead SciencesPhase 2

Magrolimab (Magrolimab)

Solid Tumor; Colorectal Cancer · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+4

효능 ORR 66.7%임상시험 30상태 DISCONTINUED

AntibodystaleJanssenApproved

teclistamab OR talquetamab OR elranatamab OR linvoseltamab (teclistamab OR talquetamab OR elranatamab OR linvoseltamab)

Waldenstrom Macroglobulinaemia; Multiple Myeloma · Waldenstrom Macroglobulinaemia

#WaldenstromMacroglobulinaemia#Antibody#Approved#항체#면역항체+3

효능 ORR 50%임상시험 30상태 RECRUITING

1 / 5 페이지

← 이전다음 →

갱신 기록 없음 · 14일 주기 · 방문 2 / 554